Third Rock Ventures — 2018 Investments
4 investments dated 2018 · listed companies and verified rows first · show all
Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics to treat serious diseases.
BiotechSouth San Francisco, US
Bernard Coulie(Executive Officer, Director)Johannes Hull(Executive Officer)Eric Lefebvre(Executive Officer)
BoardKevin Raidy(Director)
Board seatCharles HomcyNeil Exter· per SEC Form D · $62.1M raise · filed Jul 2018
Co-investorsMenlo VenturesAgent Capital
BiotechRedwood City, US
Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)
BoardLaurence Lasky(Director)Alexis Borisy(Director)Elizabeth Anderson(Director)Michael Bonney(Director)
Board seatNeil ExterBarbara Weber· per SEC Form D · $100.3M raise · filed Nov 2019
Co-investorsBain Capital Life SciencesForesite CapitalNextech Invest
BiotechCambridge, US
Stephen Hurly(Executive Officer, Director)John McCabe(Executive Officer)Arthur P. DeCillis(Executive Officer)David A. Berry(Executive Officer, Director)Gregory D. Perry(Executive Officer)Eric S. Furfine(Executive Officer)
Board seatAbbie Celniker· per SEC Form D · $996K raise · filed Apr 2018
BiotechCambridge, US
Gad Soffer(Executive Officer)Ryan Cohlhepp(Executive Officer)J. Duncan Higgons(Director)Jeffrey Bluestone(Director)Dan Matloff(Executive Officer)Sanjay Keswani(Executive Officer, Director)
Board seatAbbie CelnikerCary Pfeffer· per SEC Form D · filed Nov 2018
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.